The Life Sciences and Capital Markets team guided the underwriting syndicate, including Goldman Sachs & Co. LLC, Jefferies, and Evercore ISI as joint bookrunning managers and Wedbush PacGrow as lead manager, on Hemab Therapeutics Holdings, Inc.’s initial public offering of 19,262,500 shares of its common stock at a public offering price of $18.00 per share, inclusive of the underwriters’ option to purchase an additional 2,512,500 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by Hemab. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Hemab, are expected to be approximately $346.7 million.
Hemab Therapeutics Holdings, Inc., is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab’s mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and factor VII deficiency, and HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease.
The Goodwin team was led by Ben Marsh, Justin Platt, Jesse Fishman, Lilly Weitz, Kristopher Brown, Elizabeth Mulkey, Heath Ingram, Daniel Scolnick, Alicia Palladino, Morgan Frisoli, Justin Pierce, Nate Cunningham, Tim Worden, Lucy Sharples, Oliver Walker, Kaitlin Betancourt, Jake Lee, Jackie Klosek, Curtis McCluskey, Joseph Ndep, Dan Karelitz, and Maggie Wong.
For more information on the deal, please read the press release.